Palatin uses its expertise in the melanocortin and natriuretic peptide fields to develop next-generation peptides and mimetics addressing unmet medical needs. View our clinical pipeline.
Rekynda is a first in class melanocortin-4 receptor agonist currently in late stage clinical development for the “as needed” treatment of hypoactive sexual desire disorder in premenopausal women. Learn more about Rekynda.
Treating inflammatory and autoimmune diseases using melanocortin receptor-1 peptide drug candidates. Get more information on inflammatory disease therapies we are developing.
Melanocortin-4 receptor peptide drug candidates for treating obesity, diabetes and metabolic syndrome. View our approach to obesity and diabetes.
Natriuretic peptide synthetic mimetics for treating heart failure and related indications. Learn more about treating heart failure using natriuretic peptide mimetics.